Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy : Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study
© 2021 Wiley Periodicals LLC..
EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Dermatologic therapy - 35(2022), 1 vom: 20. Jan., Seite e15166 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 01.04.2022 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/dth.15166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332168182 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332168182 | ||
| 003 | DE-627 | ||
| 005 | 20231225215036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/dth.15166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332168182 | ||
| 035 | |a (NLM)34676662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Colombo, Delia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy |b Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional (CANOVA) study was aimed at providing real-world evidence of the effectiveness of biologics in Italian patients with moderate-severe psoriasis. It was an observational, retro-prospective cohort study conducted in 17 Italian dermatology clinics. Adult patients with moderate-severe plaque psoriasis, who started a biologic treatment between 24 weeks and 24 months before enrolment, were included. With a follow-up visit at 6 months after enrolment, each patient had at least 12 months of observation. The primary objective was to describe the clinical response rates (PASI 75) after 16/24/52 weeks from biologic treatment start. Secondary outcomes were sustained response, quality of life, and treatment satisfaction. Of the 669 eligible patients (64% males), 52% were naïve to biologics, though a mean duration of psoriasis since first diagnosis of 18.6 years (SD 13.2). The most frequently prescribed biologics were secukinumab (41%), ustekinumab (25%), TNF-inhibitors (22%) and ixekizumab (12%). PASI 75 was achieved by 86% of patients (95% CI: 82%-89%) at 16 weeks, 90% (87%-93%) at 24 weeks, and 91% (89%-94%) at 52 weeks. Patients achieving PASI 90 and PASI 100 at 52 weeks were 75% (71%-79%) and 53% (49%-57%), respectively. Sustained PASI 75 response after 1 year from treatment start was achieved by 78% (74%-82%) of patients. Mean DLQI total score was 2.3 (SD 3.9) at enrollment and decreased at the final visit to 1.8 (3.6). A high level of treatment satisfaction was expressed by patients over the study period. This large real-world study confirms in the clinical practice the good effectiveness and acceptability of biologics in psoriasis patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a biologics | |
| 650 | 4 | |a effectiveness | |
| 650 | 4 | |a patient-reported outcomes | |
| 650 | 4 | |a plaque psoriasis | |
| 650 | 4 | |a real-world | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 700 | 1 | |a Bianchi, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Fabbrocini, Gabriella |e verfasserin |4 aut | |
| 700 | 1 | |a Corrao, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Offidani, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Stingeni, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Costanzo, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Pellacani, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Peris, Ketty |e verfasserin |4 aut | |
| 700 | 1 | |a Bardazzi, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Argenziano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffolo, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Dapavo, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Carrera, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Fargnoli, Maria Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Parodi, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Romanelli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Malagoli, Piergiorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Talamonti, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Megna, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Raspanti, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Paolinelli, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Hansel, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Narcisi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Conti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a De Simone, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Chessa, Marco Adriano |e verfasserin |4 aut | |
| 700 | 1 | |a De Rosa, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Provenzano, Eugenio |e verfasserin |4 aut | |
| 700 | 1 | |a Ortoncelli, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Moltrasio, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Fidanza, Rosaria |e verfasserin |4 aut | |
| 700 | 1 | |a Burlando, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Tonini, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Gaiani, Francesca Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Simoni, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Ori, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Fiocchi, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Zagni, Emanuela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologic therapy |d 1998 |g 35(2022), 1 vom: 20. Jan., Seite e15166 |w (DE-627)NLM096394870 |x 1529-8019 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:1 |g day:20 |g month:01 |g pages:e15166 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/dth.15166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 1 |b 20 |c 01 |h e15166 | ||